A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT

Inclusion Criteria: * Histologically confirmed, newly diagnosed supratentorial glioblastoma with unmethylated MGMT gene promoter. * Patients have undergone complete or partial tumor resection. * Able and willing to provide written informed consent and comply with the study protocol and procedures. * Eligible for radiotherapy. * Life expectancy of 6 months or more at Screening. * Women of child-bearing potential enrolled in the study must have a negative pregnancy test at screening and agree to use acceptable methods of contraception during the trial. * Men enrolled in the study with partners who are women of child-bearing potential, must be willing to use an acceptable barrier contraceptive method during the trial or have undergone successful vasectomy at least 6 months prior to entry into the study. Successful vasectomy needs to have been confirmed by semen analysis. * Karnofsky performance score (KPS)≥70. Additional inclusion criteria to be assessed within 20 days of Temferon administration: * Adequate cardiac, renal, hepatic and pulmonary function as evidenced by: * Left ventricular ejection fraction (LVEF) ≥ 45% by echo and normal electrocardiogram (ECG) or presence of abnormalities not significant for cardiac disease. * Absence of severe pulmonary hypertension; * Diffusing capacity of the lung for carbon monoxide (DLCO) \>50% and forced expiratory volume in 1 sec (FEV1) and forced expiratory vital capacity (FVC) \> 60% predicted (if non cooperative: pulse oximetry \> 95% in room air); * Serum creatinine \< 2x upper limit normal and estimated glomerular filtration rate (eGFR) ≥ 30ml/min/1.73m\^2; * Alkaline phosphatase (ALP), alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≤ 2.5 x upper limit of normal (ULN), and total bilirubin ≤ 2.0 mg/dl. * Hemoglobin ≥10 g/dL, platelet count ≥100000/mm\^3, absolute neutrophil count \>1500/mm\^3. Exclusion Criteria: * Use of other investigational agents or procedures within 4 weeks prior to study enrolment (within 6 weeks if use of long-acting agents) or participation in a previous gene therapy study. * Known hypersensitivity to carmustine (or any other nitrosurea), busulfan, thiotepa, lenograstim, plerixafor, or any excipients used in these products. * Receipt of any oral or parenteral chemotherapy or immunotherapy within 2 years of Screening. * Previous allogeneic bone marrow transplantation, kidney or liver transplant. * Clinical evidence of persistent raised intracranial pressure following surgical resection. * Clinically relevant active viral, bacterial, or fungal infection at eligibility evaluation. * Active autoimmune disease or a relevant history of important autoimmune manifestations, in particular psoriasis, systemic lupus erythematosus (SLE), rheumatoid arthritis, vasculitis, immunemediated peripheral neuropathies. * History of sarcoidosis. * History or current evidence of neuropsychiatric illness including depression, schizophrenia, bipolar disorders, impaired cognitive function, dementia or suicidal tendency. * History of severe cardiovascular disease such as prior stroke, coronary artery disease requiring intervention or unresolved arrhythmias in the past 6 months. * Evidence of any hematological neoplasm. * Positivity for human immunodeficiency virus type 1 or 2 (HIV-1, HIV-2) (serology or RNA), and/or Hepatitis B Virus Surface Antigen (HbsAg) and/or Hepatitis B Virus (HBV) DNA and/or Hepatitis C virus (HCV) RNA (or negative HCV RNA but on antiviral treatment) and/or Treponema Pallidum or Mycoplasma active infection. * Active alcohol or substance abuse within 6 months of the study. * Current pregnancy or lactation. * Known bleeding diathesis or history of abnormal bleeding, or any other known coagulation abnormalities that would contraindicate lumbar puncture for CSF or future surgery. * Use of immunosuppressants with the exception of steroids. The maximum permitted dexamethasone (or equivalent) dose is 4 mg per day.